Rapport Therapeutics terminates stock sales agreement prospectus

Rapport Therapeutics (NASDAQ: RAPP) terminated its at-the-market sales agreement prospectus effective September 8, 2025, according to a company statement.

The company ended the ATM prospectus filed with its Form S-3 registration statement related to common stock sales under a July 1, 2025 sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.

The termination means Rapport Therapeutics will not sell common stock under the agreement unless it files a new prospectus, prospectus supplement, or registration statement. The underlying sales agreement remains active despite the prospectus termination.

As of September 8, 2025, the company had not issued or sold any shares under the sales agreement, the statement said.

You May Also Be Interested In

• QNB Corp. overallotment option adds 160,714 shares at $42 each
• Abbott settles preterm formula NEC lawsuits for $670 million
• iSpecimen ships hundreds of cancer specimens internationally in 3 weeks